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Abstract
Classifying chemicals according to putative modes of action (MOAs) is of
paramount importance in the context of risk assessment. However, current methods
are only able to handle a very small proportion of the existing chemicals. We
address this issue by proposing an integrative deep learning architecture that learns
a joint representation from molecular structures of drugs and their effects on human
cells. Our choice of architecture is motivated by the significant influence of a drug’s
chemical structure on its MOA. We improve on the strong ability of a unimodal
architecture (F1 score of 0.803) to classify drugs by their toxic MOAs (Verhaar
scheme) through adding another learning stream that processes transcriptional
responses of human cells affected by drugs. Our integrative model achieves an
even higher classification performance on the LINCS L1000 dataset—the error is
reduced by 4.6%. We believe that our method can be used to extend the current
Verhaar scheme and constitute a basis for fast drug validation and risk assessment.
1 Introduction
Industrial chemistry is nowadays heavily centered around two topics of increasing concern: risk
assessment and drug regulation. Tens of thousands of new chemicals are being synthesised every
year—this calls for a faster validation process, in order to advance possible candidates to the next
drug development stage or ascertain toxicity levels before releasing chemicals into the environment.
One well-established risk assessment method is the Verhaar scheme [9], which assigns a chemical
one of four possible toxic modes of action: inert, less inert, reactive, specifically acting. This method
is entirely based on chemistry principles and determines the class of a compound using a sequence
of structural triggers that attempt to place a compound in one of the four classes [3]. However, the
scheme can only be applied to a very small percentage of the existing chemical space, as the triggers
do not have any effect on most compounds, which makes it impossible to determine their toxicity.
We propose an integrative method of learning from the transcriptional responses of human cells
exposed to chemicals and structural representations of the chemicals. Our deep learning architecture
achieves a high Verhaar classification performance (F1 score of 0.812) on chemicals used in the
LINCS L1000 project1, without requiring access to the classification rules themselves. Instead, the
model learns a rich and powerful representation from the chemicals’ effects on human cells and their
unbiased, raw structure encoded in their molecular fingerprint [2]. Consequently, any chemical can
be placed in one of the Verhaar classes if we know its effect on human cells and fingerprint (can be
easily extracted using open-source tools and databases).
2 Related work
Existing research using the LINCS transcriptomic data is based in areas which include repurposing
drugs, investigating their properties and predicting their adverse effects. Aliper et al. [1] used deep
1L1000 Connectivity Map perturbational profiles from Broad Institute LINCS Center for Transcriptomics:
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE70138
Machine Learning for Health (ML4H) Workshop at NeurIPS 2018.
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neural networks (DNNs) and support vector machines (SVMs) to learn from LINCS data corre-
sponding to 678 drugs across three cell lines. They predicted 12 therapeutic use categories derived
from the MeSH database and proposed a DNN confusion matrix approach for drug repurposing.
Iwata et al. [7] also used the LINCS data to elucidate MOAs of bioactive compounds. They first
performed pathway enrichment analysis to reveal similarly classified drugs, using previously adopted
procedures (computing the p-value of two sets of genes intersecting), then predicted the target protein
using known compound-target interactions as ground truth (via cell-based similarity search using the
Pearson correlation coefficient) and finally revealed new such interactions.
Our approach is mostly similar to the one adopted by Wang et al. [10], who integrated gene expression
(GE) data with cell multiplex-cytological (MC) profiles and the chemical structure (CS) of drugs
in the form of fingerprints to predict adverse drug reactions (ADRs). The three data types were
combined for feature selection, which yielded the 50 most predictive features that were used to learn
an L1 regularized logistic regression model. The function coefficients were averaged across 200 runs
to indicate feature importances. Extra Trees (ETs) classifiers were then trained for each ADR on GE,
MC and CS data, using the 251 drugs shared among these three data sources. The authors discovered
that the GE data had the highest prediction ability, whereas the CS and MC profiles showed similar
AUROC (area under ROC) values. Additional findings showed that integrating MC profiles with
other attributes did not significantly improve the classification performance, whereas combining CS
features with GE data resulted in better predictions of ADRs. Unlike Wang et al., we do not restrict
the model to a certain number of features and allow it to learn the best ones, providing only the raw
data (entire gene expression vectors and fingerprints) to the classifier.
3 Model and inputs
3.1 Dataset
We used two types of data for classification: (a) gene expression levels encoding the transcriptional
responses of chemicals across human cell lines, represented by a vector of 978 landmark genes, and
(b) the respective molecular fingerprints, which are bit strings encoded by binary vectors of length
1024 (see Figure 1). The goal is to place each compound (represented by the two modalities) in one
of 4 Verhaar classes.
The gene expression levels were taken from the LINCS Phase II data. The entire dataset contains
118050 samples, corresponding to individual experiments with a single compound across 12328
genes, out of which 978 are landmark genes (used to infer the remaining 11350). A portion of the
dataset (53976 examples) has been labelled according to the Verhaar classification scheme [9], which
indicates the toxicity of compounds based on their modes of action. The labels correspond to four
Verhaar classes and a fifth category—chemicals that cannot be classified by the Verhaar rules.
The architecture was trained using the 14116 examples across the first four classes enumerated in
Table 1, each of them only containing perturbations corresponding to the 978 landmark genes.
Table 1: Verhaar [9] class distribution for the labelled LINCS data, across the first four classes. The
dataset is unbalanced and each chemical is used in multiple experiments.
Description Experiments Unique chemicals
Inert chemicals 1092 26
Less inert chemicals 1949 37
Reactive chemicals 6474 104
Specifically acting chemicals 4601 31
Total 14116 198
3.2 Model architecture
We use a multimodal neural network architecture to classify the chemicals by the Verhaar scheme
(see Figure 1 for a graphical description). Two learning streams extract features separately from each
of the modalities (gene expression levels and molecular fingerprint); the resulting 1D vectors are
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Figure 1: Illustration of the integrative architecture used to classify chemical compounds. Each exam-
ple contains two inputs (vector of thresholded and averaged gene expression levels and fingerprint
binary vector) and is placed into one of the four Verhaar classes.
subsequently concatenated and a final, joint representation is learned at the tail of the model. The
classification is achieved by a softmax layer.
3.3 Data pre-processing
One chemical is always used in multiple experiments (ranging from 6 to 2310, most often 42)—and
therefore examples—across the LINCS dataset. As a consequence, the unique chemicals represented
in the labelled portion are far fewer than the number of experiments; the distribution across the four
classes is shown in Table 1. This implies that all training examples involving the same chemical
would contain the same fingerprint data, which might result in overfitting on the corresponding
learning stream in the network. In order to avoid this issue, we summarized the gene expression
vectors from all experiments that were carried out using the same chemical. The resulting summary
is then used as part of one example, along with the corresponding fingerprint vector—this reduces the
dataset size to 198 examples.
Summarization Upon inspection of all experiments that use a single chemical, we noticed that
some of the transcriptional response vectors do not exhibit high variance and are thus less informative
than others, potentially even confounding the discrimination across classes. Each set of experiments
was filtered by comparing the standard deviation of a gene expression level vector with a fixed
threshold t—we found that t = 1.25 works best for this dataset. Finally, the summary is represented
by a vector of length 2 × NUM_LANDMARK_GENES which represents the concatenation of the
element-wise sum and maximum across the filtered experiments. A graphical description of the
summarization pipeline is given in Figure 2.
4 Experiments
4.1 Evaluation procedure
We used k-fold cross-validation with k = 5 to assess the performance of our models. Both unimodal
architectures were trained for 1000 epochs and the integrative model—for 2000 epochs. All models
were trained on a batch size of 26, using the RMSprop optimizer [5], with a learning rate of 0.005
and default hyperparameters 2 otherwise.
2https://pytorch.org/docs/stable/optim.html#torch.optim.RMSprop
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concat(element-wise avg, element-wise max)y
[a1, a2, ..., a978,m1,m2, ...,m978]
Figure 2: Schematic description of the summarization pipeline described in Section 3.3. The input is
the entire set of gene expression levels corresponding to experiments with a single chemical across
the LINCS dataset. The pipeline outputs a single vector which contains the element-wise average and
maximum values of the filtered gene expression vectors.
Table 2: Results of 5-fold cross-validation for the unimodal and integrative architectures.
Model F1 score
Majority class 0.362
Gene expression 0.606
Fingerprints 0.803
Fingerprints and gene expression 0.812
The class distribution across the LINCS labelled data is unbalanced (see Table 1), which makes
accuracy an unsuitable metric—we therefore used a weighted version of the F1 score to evaluate
model performance. Accordingly, all models were trained with a weighted cross-entropy loss function,
where weights were inversely proportional to the relative class proportions.
4.2 Model parameters
Our unimodal baselines are both 3-layer perceptrons. Each layer has 256 hidden units and is followed
by an ELU activation [4], a batch normalization operation [6] and dropout regularization [8] with
p = 0.25 or p = 0.5 for the final layer.
The streams of the integrative model have the same layout as the baselines described above (256-D
layers for fingerprints, 64-D for gene expression levels—see Section 3 for details); the concatenation
operation is regularized with dropout with p = 0.25. Finally, the tail of the model is formed of two
fully-connected layers (256- and 32-D) with ELU activations and dropout layers with p = 0.5. Batch
normalization is employed starting from the concatenation point.
4.3 Results
Table 2 shows that jointly learning from gene expression levels and molecular fingerprints results
in a strong classification ability for the 4 Verhaar classes. This result improves over both unimodal
architectures, suggesting that adding information about the effects of chemicals can further enhance
the powerful discrimination capabilities of the fingerprint-only model, with respect to the Verhaar
classification scheme.
This result is particularly important for classifying the unlabelled chemicals in LINCS. As a vital
goal of this research direction, assessing the toxicity of any chemical could become a simple process
by using the integrative model. The next essential step is to validate the predictions on the unlabelled
chemicals experimentally and using expert knowledge.
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